A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at -420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in type 2 diabetes

Endocrine Journal

Volumn 56, Issue 9, 2009, Pages 1049-1058

  Makino, Hideichi ^a,b   Shimizu, Ikki ^c   Murao, Satoshi ^d   Kondo, Shiori ^e   Tabara, Yasuharu ^b   Fujiyama, Masao ^f   Fujii, Yasuhisa ^a   Takada, Yasuharu ^g   Nakai, Kazuaki ^h   Izumi, Kenichi ^e   Ohashi, Jun ⁱ   Kawamura, Ryoichi ^b   Yamauchi, Junko ^b   Takata, Yasunori ^b   Nishida, Wataru ^b   Hashiramoto, Mitsuru ^b   Onuma, Hiroshi ^b,j   Osawa, Haruhiko ^b,j  

^a Takanoko Hospital   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

^d Matsuyama Shimin Hospital   (Japan)

^e MATSUYAMA RED CROSS HOSPITAL   (Japan)

^f Fujiyama Clinic   (Japan)

^g Saiseikai Saijo Hospital   (Japan)

^h N   (Japan)

ⁱ UNIVERSITY OF TSUKUBA   (Japan)

^j EHIME UNIVERSITY   (Japan)

more..

Author keywords

Insulin resistance; Pioglitazone; Resistin; SNP; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; GLINIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; RESISTIN; SULFONYLUREA; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENDER; GENE; GENOTYPE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; PREDICTION; REGRESSION ANALYSIS; RETN GENE; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HOMOZYGOTE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PHARMACOGENETICS; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RESISTIN; RETROSPECTIVE STUDIES; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 74749093514     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K08E-320     Document Type: Article

References (41)

1. Spiegelman BM (1998) PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-514.
2. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427-2443.
3. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA (2001) Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24: 710-719.
4. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH (2004) One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 27: 141-147.
5. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB, Sr., Perez A, Provost JC, Haffner SM (2006) Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296: 2572-2581.
6. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro-Vascular Events): a randomised controlled trial. Lancet 366: 1279-1289.
7. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471.
8. Kawamori R, Kadowaki T, Onji M, Seino Y, Akanuma Y (2007) Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: postmarketing surveillance study in Japan. Diabetes Res Clin Pract 76: 229-235.
9. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H, Nakao K (2003) Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26: 2493-2499.
10. Hansen L, Ekstrom CT, Tabanera YPR, Anant M, Wassermann K, Reinhardt RR (2006) The Pro12A1a variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients. J Clin Endocrinol Metab 91: 3446-3450.
11. Kang ES, Cha BS, Kim HJ, Kim HJ, Kim SH, Hur KY, Lee HJ, Shim WS, Ahn CW, Lee HC (2006) The 11482G >A polymorphism in the perilipin gene is associated with weight gain with rosiglitazone treatment in type 2 diabetes. Diabetes Care 29: 1320-1324.
12. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA (2001) The hormone resistin links obesity to diabetes. Nature 409: 307-312.
13. Banerjee R, Rangwala S, Shapiro J, Rich A, Rhoades B, Qi Y, Wang J, Rajala M, Pocai A, Scherer P, Steppan C, Ahima R, Obici S, Rossetti L, Lazar M (2004) Regulation of fasted blood glucose by resistin. Science 303: 1195-1198.
14. Rangwala S, Rich A, Rhoades B, Shapiro J, Obici S, Rossetti L, Lazar M (2004) Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 53: 1937-1941.
15. Patel L, Buckels A, Kinghorn I, Murdock P, Holbrook J, Plumpton C, Macphee C, Smith S (2003) Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 300: 472-476.
16. Savage D, Sewter C, Klenk E, Segal D, Vidal-Puig A, Considine R, O'Rahilly S (2001) Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 50: 2199-2202.
17. Weisberg S, McCann D, Desai M, Rosenbaum M, Leibel R, Ferrante AJ (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808.
18. C ho Y, Youn B, Chung S, Kim K, Lee H, Yu K, Park H, Shin H, Park K (2004) Common genetic polymorphisms in the promoter of resistin gene are major determinants of plasma resistin concentrations in humans. Diabetologia 47: 559-565.
19. Engert JC, Vohl MC, Williams SM, Lepage P, Loredo-Osti JC, Faith J, Dore C, Renaud Y, Burtt NP, Villeneuve A, Hirschhorn JN, Altshuler D, Groop LC, Despres JP, Gaudet D, Hudson TJ (2002) 5' flanking variants of resistin are associated with obesity. Diabetes 51: 1629-1634.
20. McTernan P, Fisher F, Valsamakis G, Chetty R, Harte A, McTernan C, Clark P, Smith S, Barnett A, Kumar S (2003) Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 88: 6098-6106.
21. Osawa H, Onuma H, Murakami A, Ochi M, Nishimiya T, Kato K, Shimizu I, Fujii Y, Ohashi J, Makino H (2002) Systematic search for single nucleotide polymorphisms in the resistin gene: The absence of evidence for the association of three identified single nucleotide polymorphisms with Japanese type 2 diabetes. Diabetes 51: 863-866.
22. Osawa H, Onuma H, Ochi M, Murakami A, Yamauchi J, Takasuka T, Tanabe F, Shimizu I, Kato K, Nishida W, Yamada K, Tabara Y, Yasukawa M, Fujii Y, Ohashi J, Miki T, Makino H (2005) Resistin SNP-420 determines its monocyte mRNA and serum levels inducing type 2 diabetes. Biochem Biophys Res Commun 335: 596-602.
23. Smith S, Bai F, Charbonneau C, Janderova L, Argyropoulos G (2003) A promoter genotype and oxidative stress potentially link resistin to human insulin resistance. Diabetes 52: 1611-1618.
24. Osawa H, Yamada K, Onuma H, Murakami A, Ochi M, Kawata H, Nishimiya T, Niiya T, Shimizu I, Nishida W, Hashiramoto M, Kanatsuka A, Fujii Y, Ohashi J, Makino H (2004) The G/G genotype of a resistin sin gle-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet 75: 678-686.
25. Osawa H, Tabara Y, Kawamoto R, Ohashi J, Ochi M, Onuma H, Nishida W, Yamada K, Nakura J, Kohara K, Miki T, Makino H (2007) Plasma resistin, associated with single nucleotide polymorphism -420, is correlated with insulin resistance, lower HD L, and high sensitivity CRP in the Japanese general population. Diabetes Care 30: 1501-1506.
26. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-83.
27. Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, Okuno T, Inoue T, Node K, Tobe T, Inukai T, Nakano Y (2006) Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 55: 1954-1960.
28. Ridker PM (2001) High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103: 1813-1818.
29. Tokuyama Y, Osawa H, Ishizuka T, Onuma H, Matsui K, Egashira T, Makino H, Kanatsuka A (2007) Serum resistin level is associated with insulin sensitivity in Japanese type 2 diabetes. Metabolism 56: 693-698.
30. Qatanani M, Szwergold N, Greaves D, Ahima R, Lazar M (2009) Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J Clin Invest in press.
31. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptorgamma is a negative regulator of macrophage activation. Nature 391: 79-82.
32. Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA (2004) Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 28: 783-789.
33. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA (2004) An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 1: e45.
34. Sugawara A, Takeuchi K, Uruno A, Ikeda Y, Arima S, Kudo M, Sato K, Taniyama Y, Ito S (2001) Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology 142: 3125-3134.
35. Chung SS, Choi HH, Kim KW, Cho YM, Lee HK, Park KS (2005) Regulation of human resistin gene expression in cell systems: an important role of stimulatory protein 1 interaction with a common promoter polymorphic site. Diabetologia 48: 1150-1158.
36. Chung SS, Choi HH, Cho YM, Lee HK, Park KS (2006) Sp1 mediates repression of the resistin gene by PPARgamma agonists in 3T3-L1 adipocytes. Biochem Biophys Res Commun 348: 253-258.
37. Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26: 439-451.
38. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7: 941-946.
39. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8: 731-737.
40. Bouskila M, Pajvani UB, Scherer PE (2005) Adiponectin: a relevant player in PPARgamma-agonistmediated improvements in hepatic insulin sensitivity? Int J Obes (Lond) 29 Suppl 1: S17-23.
41. Kubota N, Terauchi Y, Kubota T, Kumagai H, Itoh S, Satoh H, Yano W, Ogata H, Tokuyama K, Takamoto I, Mineyama T, Ishikawa M, Moroi M, Sugi K, Yamauchi T, Ueki K, Tobe K, Noda T, Nagai R, Kadowaki T (2006) Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem 281: 8748-8755.